Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway

Neuro-Oncology

Volumn 14, Issue 3, 2012, Pages 302-314

  Lin, Jia Wei ^a   Chen, Juei Tai ^b   Hong, Chung Ye ^b   Lin, Yi Ling ^b   Wang, Kuan Ting ^c   Yao, Chih Jung ^d   Lai, Gi Ming ^d   Chen, Ruei Ming ^b,c,d  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

apoptosis; blood brain barrier; honokiol; neuroblastoma; signal transducing events

Indexed keywords

CASPASE; CASPASE 3; CASPASE 6; CASPASE 9; CYTOCHROME C; HONOKIOL; PROTEIN BAX;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; CELL CULTURE; CELL DEATH; CELL VIABILITY; DNA FRAGMENTATION; ENDOTHELIUM CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; CYTOCHROMES C; DNA FRAGMENTATION; ENDOTHELIAL CELLS; HUMANS; LIGNANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED ICR; MITOCHONDRIA; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-BCL-2; TIGHT JUNCTIONS;

EID: 84859555338     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor217     Document Type: Article

References (45)

1. van der Pal HJ, van Dalen EC, Kremer LC, et al. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev. 2005;31:173-185. (Pubitemid 40790389)
2. Hoehner JC, Gestblom C, Hedborg F, et al. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest. 1996;75:659-675. (Pubitemid 26392797)
3. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008;55:97-120. (Pubitemid 351173188)
4. Pearson AD, Pinkerton CR, Lewis IJ, et al. European Neuroblastoma Study Group, Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group). High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247-256. (Pubitemid 351722944)
5. Laverdiè re C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005;45:324-332. (Pubitemid 41077167)
6. Zage PE, Kletzel M, Murray K, et al. Children's Oncology Group. Outcomes of the POG 9340/9341/9342 trials for children with highrisk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2008;51:747-753.
7. Wagner LM, Danks MK. New therapeutic targets for the treatment of high-risk neuroblastoma. J Cell Biochem. 2009;107:46-57.
8. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173. (Pubitemid 29480654)
9. Chen L, Zhang Q, Yang G, et al. Rapid purification and scale-up of honokiol and magnolol using high-capacity high-speed counter-current chromatography. J Chromatogr A. 2007;1142:115-122. (Pubitemid 46185375)
10. Lo YC, Teng CM, Chen CF, et al. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol. 1994;47:549-553.
11. Kotani H, Tanabe H, Mizukami H, et al. Identification of a naturally occurring rexinoid, honokiol, that activates the retinoid X receptor. J Nat Prod. 2010;73:1332-1336.
12. Esumi T, Makado G, Zhai H, et al. Efficient synthesis and structureactivity relationship of honokiol, a neurotrophic biphenyl-type neolignan. Bioorg Med Chem Lett. 2004;14:2621-2625. (Pubitemid 38515715)
13. Fried LE, Arbiser JL. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal. 2009;11:1139-1148.
14. Zhai H, Nakade K, Oda M, et al. Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2). Eur J Pharmacol. 2005;516:112-117. (Pubitemid 40799346)
15. Lin YR, Chen HH, Ko CH, et al. Neuroprotective activity of honokiol and magnolol in cerebellar granule cell damage. Eur J Pharmacol. 2006;537:64-69.
16. Wang X, Duan X, Yang G, et al. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS One. 2011;6:e18490.
17. Doolittle ND, Anderson CP, Bleyer WA, et al. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium. Neuro Oncol. 2001;3:46-54. (Pubitemid 33685586)
18. Engelhardt B. Development of the blood-brain barrier. Cell Tissue Res. 2003;314:119-129. (Pubitemid 37409918)
19. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41-53. (Pubitemid 41828930)
20. Rubin LL. Endothelial cells: adhesion and tight junctions. Curr Opin Cell Biol. 1992;4:830-833.
21. Raja SM, Chen S, Yue P, et al. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther. 2008;7:2212-2223.
22. Goyal L. Cell death inhibition: keeping caspases in check. Cell. 2001;104:805-808. (Pubitemid 32289272)
23. Chen RM, Chen TL, Chiu WT, et al. Molecular mechanism of nitric oxide-induced osteoblast apoptosis. J Orthop Res. 2005a;23:462-468.
24. Pagliari LJ, Kuwana T, Bonzon C, et al. The multidomain proapoptotic molecules Bax and Bak are directly activated by heat. Proc Natl Acad Sci USA. 2005;102:17975-17980. (Pubitemid 41798487)
25. Saikumar P, Dong Z, Patel Y, et al. Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene. 1998;17:3401-3415. (Pubitemid 29050675)
26. Rao L, Perez D, White E. Lamin proteolysis facilitates nuclear events during apoptosis. J Cell Biol. 1996;135:1441-1455. (Pubitemid 26427643)
27. Jiang QQ, Fan LY, Yang GL, et al. Improved therapeutic effectiveness by combining liposomal honokiol with cisplatin in lung cancer model. BMC Cancer. 2008;8:242.
28. Xu J, Yeh CH, Chen S, et al. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-a/cycloheximide-induced cerebral endothelial cell death. J Biol Chem. 1998;273:16521-16526. (Pubitemid 28311437)
29. Chen TG, Chen TL, Chang HC, et al. Oxidized low-density lipoprotein induces apoptotic insults to mouse cerebral endothelial cells via a Bax-mitochondria-caspase protease pathway. Toxicol Appl Pharmacol. 2007;219:42-53.
30. Chang HC, Chen TG, Tai YT, et al. Resveratrol attenuates oxidized LDL-evoked Lox-1 signaling and consequently protects against apoptotic insults to cerebrovascular endothelial cells. J Cereb Blood Flow Metab. 2011;31:842-854.
31. Lin YL, Chang HC, Chen TL, et al. Resveratrol protects against oxidized LDL-induced breakage of the blood-brain barrier by lessening disruption of tight junctions and apoptotic insults to mouse cerebrovascular endothelial cells. J Nutr. 2010;140:2187-2192.
32. Tang W, Wan M, Zhu Z, et al. Simultaneous determination of eight major bioactive compounds in Dachengqi Tang (DT) by highperformance liquid chromatography. Chinese Med. 2008;3:5.
33. Huang TY, Chen TL, Liao MH, et al. Drynaria fortunei J. Sm. promotes osteoblast maturation by inducing differentiation-related gene expression and protecting against oxidative stress-induced apoptotic insults. J Ethnopharmacol. 2010;131:70-77.
34. Chen RM, Chen TL, Lin YL, et al. Ketamine reduces nitric oxide biosynthesis in human umbilical vein endothelial cells through downregulating endothelial nitric oxide synthase expression and intracellular calcium levels. Crit Car Med. 2005;33:1044-1049.
35. Chang CC, Liao YS, Lin YL, et al. Nitric oxide protects osteoblasts from oxidative stress-induced apoptotic insults via a mitochondria-dependent mechanism. J Orthop Res. 2006;24:1917-1925.
36. Wu GJ, Chen TG, Chang HC, et al. Nitric oxide from both exogenous and endogenous sources activates mitochondria-dependent events and induces insults to human chondrocytes. J Cell Biochem. 2007;101:1520-1531.
37. Tai YT, Cherng YG, Chang CC, et al. Pretreatment with low nitric oxide protects osteoblasts from high nitric oxide-induced apoptotic insults through regulation of c-Jun N-terminal kinase/c-Jun-mediated Bcl-2 gene expression and protein translocation. J Orthop Res. 2007;25:625-635.
38. Cherng YG, Chang HC, Lin YL, et al. Apoptotic insults to human chondrocytes induced by nitric oxide are involved in sequential events, including cytoskeletal remodeling, phosphorylation of mitogen-activated protein kinase kinase kinase-1, and Bax-mitochondria-mediated caspase activation. J Orthop Res. 2008;26:1018-1026.
39. Ho WP, Chan WP, Hsieh MS, et al. Runx2-mediated Bcl-2 gene expression contributes to nitric oxide protection against oxidative stress-induced osteoblast apoptosis. J Cell Biochem. 2009;108:1084-1093.
40. Chen RM, Lin YL, Chou CW. GATA-3 transduces survival signals in osteoblasts through upregulation of bcl-xL gene expression. J Bone Min Res. 2010;25:2193-2204.
41. Huber JD, Egleton RD, Davis TP. Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 2001;24:719-725. (Pubitemid 33097539)
42. Siddharthan V, Kim YV, Liu S, et al. Human astrocytes/ astrocyteconditioned medium and shear stress enhance the barrier properties of human brain microvascular endothelial cells. Brain Res. 2007;1147:39-50. (Pubitemid 46574560)
43. dos Santos LV, Carvalho AL. Bcl-2 targeted-therapy for the treatment of head and neck squamous cell carcinoma. Recent Pat Anticancer Drug Discov. 2011;6:45-57.
44. Garrido C, Galluzzi L, Brunet M, et al. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 2006;13:1423-1433. (Pubitemid 44210346)
45. Li Z, Tan F, Liewehr DJ, et al. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J Natl Cancer Inst. 2010;102:758-770.